Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors. - Schneider MA; Linecker M; Fritsch R; Muehlematter UJ; Stocker D; Pestalozzi B; Samaras P; Jetter A; Kron P; Petrowsky H; Nicolau C; Lehn JM; et al. (Nature communications, 2021)